However, the use of minichromosomes reconstituted in aXenopusegg extract precluded determination of binding dynamics in the context of the nucleosomal dyad, and a direct role for MeCP2 in competitive exclusion of H1 was not established

However, the use of minichromosomes reconstituted in aXenopusegg extract precluded determination of binding dynamics in the context of the nucleosomal dyad, and a direct role for MeCP2 in competitive exclusion of H1 was not established. component in transcriptional regulation, with methylation generally leading to repression of nearby genes (6). However, the mechanism by which the epigenetic signal is passed to the regulatory machinery is not well understood. Research in this area has been focused on a small family of methyl-CpG binding proteins, best characterized by MeCP2 (19), mutations in which result in Rett syndrome (RTT), a debilitating neurodevelopmental disease in humans (2). A mechanism of MeCP2-mediated gene silencing may Ibuprofen Lysine (NeoProfen) involve recruitment of histone deacetylases upon methyl-specific binding (57). However, other mechanisms, which are not necessarily mutually exclusive, such as stabilization of large chromatin loops (29) and promotion of chromatin compaction (51), have also been suggested (14). Studies onin vivodistribution of MeCP2 in nuclei have revealed that, in addition to the expected occupancy of sites of Ibuprofen Lysine (NeoProfen) CpG methylation, MeCP2 shows significant binding to unmethylated DNA (71). However, a recent analysis of MeCP2 occupancy has revealed that the genomic distribution of MeCP2 in mammalian neurons closely tracks methyl-CpG density (60). These results highlight our current lack of understanding of key questions pertinent to the binding of MeCP2 to DNA and chromatin. It is especially important, for example, to quantitate the modulation of binding by factors such as methylation density (8,37,48,60) and the presence of adjacent A/T-rich sequences (31) that are reported to influence binding. In the present work, we Ibuprofen Lysine (NeoProfen) have used a variety of quantitative approaches to show that, when bound to DNA, MeCP2 exhibits a cooperative monomer-dimer equilibrium, which is influenced by DNA length, methylation density, and the presence of nearby A/T repeats. The interaction of MeCP2 with mononucleosomes is similar to its binding to naked DNA and strongly influenced by DNA methylation. The primary binding site in the linker DNA entry/exit region is reminiscent of histone H1 binding, which induces specific changes in chromatin architecture (5). In this report, using direct electron microscopy Ibuprofen Lysine (NeoProfen) (EM) imaging of tetra-nucleosomes, we show that, like H1 binding, MeCP2 binding induces compaction by dramatically reducing the Rabbit Polyclonal to TEP1 nucleosomal linker DNA entry/exit angle. Further, the steady-state fluorescence anisotropy studies reported here demonstrate competitive binding to methylated chromatosomes and reveal that MeCP2 is more potent at displacing H1 than vice versa. In vivo, both linker histone H1 (36,46) and MeCP2 (31,32) have similar levels of intranuclear mobility and,in vitro, share binding sites on nucleosomes, suggesting that they may compete for chromatin binding. A competitive binding equilibrium between them would have important consequences for their nucleosome occupancy. Our fluorescence-recovery-after-photobleaching (FRAP) analysis reveals thatin vivochromatin binding by MeCP2 and the well-characterized histone H1 variant H10follows a complex competitive equilibrium. Together, these data suggest that there is a dynamic interplay between MeCP2 and H10that modulates local chromatin structure. Nevertheless, there are binding sites that are tightly bound either by MeCP2 or by H1 and cannot be exchanged by increasing the abundance of the other. These findings may explain the wide range of phenotypes associated with different levels of MeCP2 abundance and diversity of RTT mutations. == MATERIALS AND METHODS == == MeCP2 and H10. == For synthesizing monocysteine (Cys413) MeCP2, site-directed-mutagenesis primers were designed to convert the two other cysteines (Cys339 and -429) to alanine. For cysteine-to-alanine conversion of Cys339, the pair of primers used were 5 GGGAAAGGACTGAAGACCgcTAAGAGCCCTGGGCGGAAAAG 3 and 5 CTTTTCCGCCCAGGGCTCTTAgcGGTCTTCAGTCCTTTCCC 3, and for cysteine-to-alanine conversion of Cys429, the pair of primers used were 5 CACTGGAGAGCGACGGCgcCCCCAAGGAGCCAGCTAAG 3 and 5.

---